Today's Top 5
5. mRNA Vaccines to Fight Cancer
Beyond Covid-19: mRNA vaccines fight cancer in phase 3 trial
— Sunandana Chandra, MD (@MunTheLoon) September 22, 2021
Thanks @ChiHealthMag for featuring this intriguing treatment paradigm in cancer. https://t.co/Fp2ubqSVA0
4. Podcast: Pulmonary Stents for Cancer Patients
This week on the @ClevelandClinic Cancer Advances podcast, I talk to @CleClinicMD Tom Gildea, Section Head of Bronchology about innovative customized pulmonary stents for patients with #cancer. @TRGildea #CleClinicCancer https://t.co/OGgR0Rrwlr
— Dale Shepard MD, PhD (@ShepardDale) October 15, 2021
3. Adjuvant Immunotherapy Approved for NSCLC
Adjuvant immunotherapy for NSCLC @FDAOncology approved! Atezolizumab (anti-PDL1) approved for resected stage II-III, PDL1+ NSCLC. Based on randomized phase III IMpower 010 which showed DFS HR 0.66 in this population (HR 0.43 in PDL1 high). #LCSM @OncoAlerthttps://t.co/lRDsie07Vp
— Stephen V Liu (@StephenVLiu) October 15, 2021
2. Hematologic Malignancies and COVID
This is exactly right. We have actually published on this: patients with hematologic malignancies are compromised in multiple aspects when combatting COVID. First, many treatments for multiple myeloma suppress antibody responses to vaccination: https://t.co/WGfyii8jCw https://t.co/IbcMifFz1x
— Santosh Vardhana (@SantoshVardhana) October 18, 2021
1. SCLC Subtypes
SCLC has various subtypes defined by differential expression of ASCL1, NEUROD1 & POU2F3 (SCLC-A, -N, & -P). A new PLCG2-high SCLC phenotype with poor survival appears to be profibrotic & associated with immunosuppressive monocyte/macrophages.https://t.co/nJGr0oPSMM pic.twitter.com/pLt564QcO7
— soria (@jsoriamd) October 18, 2021